Stein, MD, professor and co-director of the Acute Leukemia Program at City of Hope in Duarte, California, provides deeper insight into the trial design and key findings in an interview with Targeted ...
Newser on MSN12h
Was It Her 1970s Pajamas? Chemist Reflects on Her CancerWhen Alison Spodek was diagnosed with acute myeloid leukemia in 2013, she did what many new cancer patients do: wondered when ...
JP Morgan raised Syndax's price target to $41, citing strong early Revuforj sales and physician confidence in its use for acute leukemias and NPM1 AML.
Identifying the JAK2V617F mutation has improved understanding of what causes overproduction of red blood cells, platelets, ...
PLC ("TC BioPharm" or the "Company"), (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today ...
CERo’s technology works by grafting onto patients’ own T-cells a receptor that binds to a naturally occurring human antigen ...
Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) with ...
Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) with Next and Final Analysis Planned Upon Reaching 80 Events ...
Aptevo Therapeutics reports strong remission rates in AML patients using mipletamig plus ven/aza, with Cohort 2 enrollment ...
The rate of cGVHD-free survival was 78% at 1 year in patients who received Orca-T compared with 38% among patients who ...
JPMorgan raised the firm’s price target on Syndax (SNDX) to $41 from $39 and keeps an Overweight rating on the shares after having surveyed 23 ...
The journey of fighting Acute Myeloid Leukemia (AML) in India encompasses severe physical and emotional challenges for both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback